Abstract
In the present study, a protocol was developed for processing of human adipose derived mesenchymal stem cell secretome formulation of varying concentration. Its molecular composition was evaluated, and its effectiveness in vitro using breast cancer cell lines, and in vivo in a nude mice breast cancer model was studied to determine its role in suppressing triple negative breast cancer in a dose dependent manner. Because the secretome could have value as an add-on therapy along with a current drug, the effectiveness of the secretome both in monotherapy and in combination therapy along with paclitaxel was evaluated. The results showed significant cell kill when exposed to the secretome above 20 mg/ml at which concentration there was no toxicity to normal cells. 70 mg/ml of SF showed 90 ± 10% apoptosis and significant decrease in CD44+/CD24−, MDR1+ and PDL-1+ cancer cells. In vivo, the tumor showed no growth after daily intra tumor injections at 50 mg/ml and 100 mg/ml doses whereas substantial tumor growth occurred after saline intra tumor injection. The study concludes that SF is a potential biotherapeutic for breast cancer and could be used initially as an add-on therapy to other standard of care to provide improved efficacy without other adverse effects.
Highlights
In the present study, a protocol was developed for processing of human adipose derived mesenchymal stem cell secretome formulation of varying concentration
The results reported by Schneider et al.[37] and Kanehiraet al.[38], showed that the conditioned media derived from mesenchymal stem cells isolated from a healthy physiological source have the ability to inhibit cancer cell growth
We develop a protocol for the use of human adipose derived mesenchymal stem cell (MSC) secretome to create a formulation with well-defined secretome concentration, evaluate its molecular composition, and explore its effectiveness, in vitro and in vivo, in suppressing breast cancer in a dose dependent manner
Summary
A protocol was developed for processing of human adipose derived mesenchymal stem cell secretome formulation of varying concentration. We use in vitro and in vivo models of triple negative breast cancer[3] (TNBC) lacking estrogen, progesterone and human epidermal growth factor 2 (HER2) receptors which is an aggressive form of breast cancer showing c hemo[4,5] and immune resistant phenotype with poor response to targeted therapies[6,7] to evaluate the anti-cancer potential. The stem cell conditioned media has shown the opposite effect in some cases, namely promotion of cancer[46,47,48,49,50]. Development of a stem cell secretome formulation which can reproducibly demonstrate the suppression of cancer is essential
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
